---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-25-005284"
form_type: "8-K"
ticker: "CNSP"
cik: "0001729427"
company_name: "CNS Pharmaceuticals, Inc."
filed_at: "2025-07-22T23:59:59+00:00"
generated_at: "2026-05-18T04:24:28.574235+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# CNS Pharmaceuticals announces 1-for-12 reverse stock split effective July 22, 2025

## Summary
- Reverse split reduces outstanding shares from ~6.36M pre-split to ~529,829 post-split.
- Authorized common shares reduced from 300M to 25M; preferred from 5M to 416,667.
- No fractional shares; cash in lieu for odd lots.
- CUSIP changes to 18978H508; trading symbol CNSP unchanged.
- Historical per-share data recast: FY2024 basic loss per share goes from ($38.87) pre-split to ($466.43) post-split.

## SEC filing metadata
- accession: 0001683168-25-005284
- form_type: 8-K
- ticker: CNSP
- cik: 0001729427
- company_name: CNS Pharmaceuticals, Inc.
- filed_at: 2025-07-22T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 3.03, 5.03, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1729427/000168316825005284/0001683168-25-005284-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1729427/000168316825005284/cns_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-25-005284
- JSON: https://secwatch.observer/filing/0001683168-25-005284.json
- Plain text: https://secwatch.observer/filing/0001683168-25-005284.txt

## Key facts
- Governance Changes
  CNS Pharmaceuticals, Inc.: Certificate of Change filed to effect a 1-for-12 reverse stock split, proportionally reducing authorized common stock from 300,000,000 to 25,000,000 and preferred stock from 5,000,000 to 416,667 (effective 2025-07-22).
  - Change: charter amendment
  - Effective: 2025-07-22
  source text: On July 17, 2025, CNS Pharmaceuticals, Inc., a Nevada corporation (the “Company”), filed with the Secretary of State of the State of Nevada a Certificate of Change (the “Certificate of Change”), pursuant to Nevada Revised Statutes 78.209, to effect a one-for-twelve (1-for-12) reverse stock split (the “Reverse Split”) of the Company’s issued and outstanding common stock, par value $0.001 per share (the “Common Stock”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1729427/000168316825005284/0001683168-25-005284-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.